Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
October 18, 2024 06:47 ET
|
Novartis Pharma AG
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment...
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
October 17, 2024 09:15 ET
|
Renovaro Inc
AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the...
Funds urgently needed to support frontline heroes in a difficult world
October 15, 2024 10:55 ET
|
Primary Care Trauma Foundation
The Primary Care Trauma Foundation (PCTF) is a global charity that trains medics & lay volunteers to prepare for when the worst happens all over the world.
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
October 15, 2024 07:30 ET
|
Molecure
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as...
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
October 11, 2024 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 10, 2024 07:30 ET
|
Purple Biotech Ltd.
CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer ...
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
October 09, 2024 08:00 ET
|
Evaxion Biotech
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked...
Breast Cancer Prevention: New Research Shows Most Women Unaware About the Link Between Breast Density and Cancer
October 08, 2024 14:45 ET
|
D S Simon
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics' latest survey reveals a major knowledge gap—most women don’t know that dense breast tissue may raise their cancer risk. Recently, OB-GYN...
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT
October 08, 2024 02:45 ET
|
Hofseth Biocare ASA
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel...
Breast Cancer Screening Market to Reach $6.7 Billion, Globally, by 2033 at 8.7% CAGR: Allied Market Research
October 07, 2024 13:00 ET
|
Allied Analytics LLP
Wilmington, Delaware , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Breast Cancer Screening Market by Test Type (Blood Marker Test, Genetic Test,...